Recent advances in analytical methods for combining evidence from RCTs and non-RCTs, and the development of new frameworks for the inclusion of RWE in HTA have provided a greater insight on how issues around RWE uncertainty can be dealth with when estimating treatment effects for new technologies.

Join our panellists for a lively discussion as they debate using these novel analytical methods in HTA, and propose a newly developed framework for integrating non-RCTs in decision-making and explore acceptance of its use.